Let's Build Better Cells Together
MaxCyte® empowers scientists across cell therapy, protein production, and cell-based assay development to move further, faster—backed by 25+ years of experience and a partnership-first approach. Our Flow Electroporation® technology and SeQure DXTM services enable efficient, scalable, and precise engineering of even the most complex cell types. We support your journey from discovery to commercialization—because better partnerships build better cells.
Technology
The ExPERT™ platform is built with MaxCyte’s proven, non-viral electroporation technology designed to enable transfection with high-efficiency and scalable delivery across a wide range of applications. Built for flexibility and precision, the platform empowers researchers to engineer complex cells at any scale with confidence.
Services
Partnership
MaxCyte’s partnership-driven licensing model provides more than access to leading non-viral transfection technology—it’s a strategic pathway to clinic and commercialization. Through flexible licensing, expert support, and proven scalability, we invest in your success from day one and help you accelerate your development while mitigating risk. Learn how our model empowers your clinical success.
Our customers are priority number one for MaxCyte
Explore the research we've supported
See how MaxCyte technology is advancing our partners' biomedical innovations
Our Partners
MaxCyte News
Latest News
MaxCyte Minutes Newsletter – Q1 2025
March 27, 2025
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
MaxCyte Acquires SeQure DX to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025